In 2017, fresh off a PhD on theoretical chemistry, John Jumper heard rumors that Google DeepMind had moved on from building AI that played games with superhuman skill and was starting up a secret project to predict the structures of proteins. He applied for a job. Just three years later, Jumper celebrated a stunning win […]
Mobile Phone Addiction and Suicidal Behaviors in Adolescents: School-Based Cross-Sectional Study in Zhejiang Province, China
Background: Suicide is a critical public health issue in adolescents. Mobile phone addiction (MPA) is characterized by an impaired ability to use mobile phones appropriately, which may further induce addictive symptoms analogous to those of substance abuse disorders and exhibit a significant association with suicidal behaviors. However, the associations between MPA and suicidal behaviors have […]
Kelun’s TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities. Chengdu-based Kelun-Biotech said that a combination of its ADC …
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
Plus, news about Clearside Biomedical, Pfizer, Astellas, Merck, MindImmune Therapeutics and Poxel: 💵 Sarepta to pay Arrowhead $200M as it continues type 1 myotonic dystrophy study: Sarepta
Angelini rapped for criticism of EMA approval
Angelini has been rapped under the UK pharma industry’s code of practice for criticising licensing decisions made by the EMA and other breaches.
Disappointment as Novo’s oral GLP-1 fails in Alzheimer’s
GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer’s disease may not be among them.
Sex and age estimation from cardiac signals captured via radar using data augmentation and deep learning: a privacy concern
IntroductionElectrocardiograms (ECGs) have long served as the standard method for cardiac monitoring. While ECGs are highly accurate and widely validated, they require direct skin contact, are sensitive to motion artifacts, and are not always practical for continuous or unobtrusive monitoring, limiting their generalization to real-world, dynamic environments. However, radar-based technologies offer a novel, non-invasive alternative […]
Open LLM-based actionable incidental finding extraction from [18F]fluorodeoxyglucose PET-CT radiology reports
IntroductionWe developed an open, large language model (LLM)-based pipeline to extract actionable incidental findings (AIFs) from [18F]fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG PET-CT) reports. This imaging modality often uncovers AIFs, which can affect a patient’s treatment. The pipeline classifies reports for the presence of AIFs, extracts the relevant sentences, and stores the results in structured […]
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics
Versant Ventures’ latest startup is debuting with a partnership with Biogen to make oral macrocycles for immune and inflammatory diseases, a booming area of biopharma investment. Biogen is paying Dayra Therapeutics $50 million upfront as …
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures. The unexpected …
Stroke data breathes life back into Bayer’s asundexian
Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay disease progression in patients in two …